Ribonucleic Acid (RNA) In Situ Hybridization (ISH) Market Global Report 2026

The ribonucleic acid (RNA) in situ hybridization (ish) market size has grown rapidly in recent years. It will grow from $1.49 billion in 2025 to $1.66 billion in 2026 at a compound annual growth rate (CAGR) of 11.1%. The growth in the historic period can be attributed to growth in cancer biomarker research, expansion of academic molecular biology funding, increasing adoption of fluorescence microscopy techniques, rising prevalence of infectious disease diagnostics, development of early nucleic acid detection methods.

The ribonucleic acid (RNA) in situ hybridization (ish) market size is expected to see rapid growth in the next few years. It will grow to $2.49 billion in 2030 at a compound annual growth rate (CAGR) of 10.7%. The growth in the forecast period can be attributed to rising demand for precision oncology diagnostics, increasing adoption of spatial transcriptomics technologies, expansion of personalized medicine applications, growth in automated laboratory workflows, increasing investment in advanced genomic research infrastructure. Major trends in the forecast period include AI assisted spatial transcriptomics image analysis improving rna signal interpretation accuracy, ultra sensitive multiplex probe development enabling simultaneous multi target rna detection, automated slide hybridization platforms reducing manual error and improving throughput, advanced fluorescent imaging systems enabling high resolution intracellular rna mapping, single cell expression profiling innovations enhancing tissue level gene expression insights.

The rising infectious disease detection is expected to propel the growth of the ribonucleic acid (RNA) in situ hybridization (ISH) market going forward. Infectious disease detection refers to the growing application of diagnostic methods to identify viral, bacterial, and other pathogenic infections through molecular and laboratory-based analyses. The increase in infectious disease detection is driven by the expanding adoption of advanced molecular diagnostic technologies that provide faster and more accurate pathogen identification. RNA in situ hybridization (ISH) enhances infectious disease detection by identifying and localizing pathogen-specific RNA within tissue specimens, enabling precise visualization of infected cells while preserving tissue morphology. For instance, in May 2026, according to the UK Health Security Agency, a UK-based government agency, between 1 January and 25 May 2026, England reported 630 laboratory-confirmed measles cases, marking an increase of 88 cases compared with the previous report published on 11 May 2026. Therefore, the rising infectious disease detection is driving the growth of the ribonucleic acid (RNA) in situ hybridization (ISH) market.

The increasing adoption of precision medicine is expected to propel the growth of the ribonucleic acid (RNA) in situ hybridization (ISH) market going forward. Precision medicine is a healthcare approach that tailors disease prevention, diagnosis, and treatment based on an individual's genetic profile, biomarkers, and molecular characteristics. The adoption of precision medicine is rising due to the increasing prevalence of chronic diseases, particularly cancer, which require highly targeted and personalized treatment strategies. RNA in situ hybridization (ISH) supports precision medicine by detecting and localizing specific RNA biomarkers within tissue samples, facilitating molecular profiling that guides targeted therapies and enhances patient-specific treatment outcomes. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based hospital and healthcare organization, in 2023, the FDA approved 16 new personalized treatments for patients with rare diseases, up from six in 2022. Therefore, the increasing adoption of precision medicine is driving the growth of the ribonucleic acid (RNA) in situ hybridization (ISH) market.

Major companies operating in the ribonucleic acid (RNA) in situ hybridization (ISH) market are prioritizing strategic partnerships to advance workflow automation, enhance RNA biomarker visualization, improve diagnostic accuracy, and support high-throughput molecular pathology analysis. Strategic partnerships are collaborative agreements between organizations that combine resources, expertise, or capabilities to achieve common objectives, expand market reach, and foster mutual growth. For instance, in March 2026, Leica Biosystems Nussloch GmbH, a Germany-based medical technology manufacturer, partnered with Bio-Techne Corporation, a US-based life sciences company, to introduce BOND-PRIME RNAscope Brown Detection, designed to enhance automated chromogenic RNA in situ hybridization workflows, improve RNA biomarker visualization, and support high-throughput digital pathology and molecular diagnostics applications. Its key distinguishing feature is the fully automated integration of the RNAscope in situ hybridization (ISH) workflow with the BOND-PRIME Staining Platform, enabling faster, standardized RNA biomarker detection while minimizing manual intervention.

Major companies operating in the ribonucleic acid (RNA) in situ hybridization (ish) market report are Roche Diagnostics International AG, Thermo Fisher Scientific Inc., Merck KGaA, Danaher Corporation, Agilent Technologies Inc., Charles River Laboratories, QIAGEN N.V., Bio-Techne Corporation, Akoya Biosciences Inc., Biocare Medical LLC, Biogenex Laboratories Inc., Empire Genomics LLC, BioChain Institute Inc., Boster Biological Technology Co. Ltd., AnaPath Services GmbH, Bio SB Inc., Enzo Biochem Inc.

North America was the dominating region in the ribonucleic acid (RNA) in situ hybridization (ISH) market in 2025. Asia-Pacific is expected to be the rapidly growing region in the forecast period. The regions covered in the ribonucleic acid (RNA) in situ hybridization (ISH) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the ribonucleic acid (RNA) in situ hybridization (ISH) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

This product will be delivered within 3-5 business days.